Combination treatment of Cetuximab and Wnt inhibitor mitigated tumor growth in CHD6-high human patient-derived xenograft (PDX) CRC model with better efficacy through hindering CHD6-TMEM65 signaling axis. This evidence concerns the gene TMEM65 and neoplasm.